Raffaele Dicaprio

[Raffaele Dicaprio @RaffaeleDi72001]

@earthling_777 🤞🆘🫀

[Raffaele Dicaprio @RaffaeleDi72001]

$ADGM garbage

[Raffaele Dicaprio @RaffaeleDi72001]

@earthling_777 Eh.....🤞

[Raffaele Dicaprio @RaffaeleDi72001]

$ADGM garbage

[Raffaele Dicaprio @RaffaeleDi72001]

@87_trades Tnks

[Raffaele Dicaprio @RaffaeleDi72001]

$adgm 🫀🫀🫀🫀🆘🆘🆘🚑🚑🚑

[Raffaele Dicaprio @RaffaeleDi72001]

🫀🫀🫀🫀🆘🆘🆘🚑🚑🚑🚑🚑$adgm

[Raffaele Dicaprio @RaffaeleDi72001]

$adgm when 2

[Raffaele Dicaprio @RaffaeleDi72001]

@87_trades

[Raffaele Dicaprio @RaffaeleDi72001]

@earthling_777 ✝️

[Raffaele Dicaprio @RaffaeleDi72001]

$adgm garbage

[Raffaele Dicaprio @RaffaeleDi72001]

$adgm✝️

[Raffaele Dicaprio @RaffaeleDi72001]

@87_trades 💆🤞

[Raffaele Dicaprio @RaffaeleDi72001]

$adgm when 2

[Raffaele Dicaprio @RaffaeleDi72001]

$adgm cmonn

[sam jaros @samjaros]

$ADGM @ .99 news Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“VT”) in patients with ischemic or non-ischemic structural heart disease.

[Raffaele Dicaprio @RaffaeleDi72001]

@samjaros 💆🤞🆘

[Raffaele Dicaprio @RaffaeleDi72001]

@87_trades ✝️🚑

[Raffaele Dicaprio @RaffaeleDi72001]

@earthling_777 @87_trades 🤞